334 related articles for article (PubMed ID: 19453778)
1. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis.
Baran R; Tosti A; Hartmane I; Altmeyer P; Hercogova J; Koudelkova V; Ruzicka T; Combemale P; Mikazans I
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):773-81. PubMed ID: 19453778
[TBL] [Abstract][Full Text] [Related]
2. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
[TBL] [Abstract][Full Text] [Related]
3. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
Avner S; Nir N; Henri T
J Dermatolog Treat; 2005; 16(5-6):327-30. PubMed ID: 16428154
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.
Zalacain-Vicuña AJ; Nieto C; Picas J; Martínez H; Bermejo R; Corrales A; Campos FF; Igea SA; Otero-Espinar FJ; Briones VG
Mycoses; 2023 Jul; 66(7):566-575. PubMed ID: 36336989
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
[TBL] [Abstract][Full Text] [Related]
6. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Gupta AK; Fleckman P; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
[TBL] [Abstract][Full Text] [Related]
7. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
[TBL] [Abstract][Full Text] [Related]
8. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study.
Gupta AK;
J Drugs Dermatol; 2005; 4(4):481-5. PubMed ID: 16004022
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
Seebacher C; Nietsch KH; Ulbricht HM
Cutis; 2001 Aug; 68(2 Suppl):17-22. PubMed ID: 11665724
[TBL] [Abstract][Full Text] [Related]
10. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
[TBL] [Abstract][Full Text] [Related]
11. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective.
Gupta AK; Schouten JR; Lynch LE
Skin Therapy Lett; 2005 Sep; 10(7):1-3. PubMed ID: 16292454
[TBL] [Abstract][Full Text] [Related]
12. Antifungal activity, experimental infections and nail permeation of an innovative ciclopirox nail lacquer based on a water-soluble biopolymer.
Togni G; Mailland F
J Drugs Dermatol; 2010 May; 9(5):525-30. PubMed ID: 20480796
[TBL] [Abstract][Full Text] [Related]
13. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Sidou F; Soto P
Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
[TBL] [Abstract][Full Text] [Related]
14. Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta AK
Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
[TBL] [Abstract][Full Text] [Related]
15. Ciclopirox nail lacquer topical solution 8%.
Gupta AK
Skin Therapy Lett; 2000; 6(1):1-5. PubMed ID: 11027420
[TBL] [Abstract][Full Text] [Related]
16. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.
Brenner MA; Harkless LB; Mendicino RW; Page JC
J Am Podiatr Med Assoc; 2007; 97(3):195-202. PubMed ID: 17507527
[TBL] [Abstract][Full Text] [Related]
17. Treatment costs of three nail lacquers used in onychomycosis.
Marty JP; Lambert J; Jäckel A; Adjadj L
J Dermatolog Treat; 2005; 16(5-6):299-307. PubMed ID: 16428149
[TBL] [Abstract][Full Text] [Related]
18. A-Detail fact sheet (Canada). Ciclopirox 8% nail lacquer (Penlac).
Skin Therapy Lett; 2005 Dec-2006 Jan; 10(10):suppl 1 p.. PubMed ID: 16518906
[No Abstract] [Full Text] [Related]
19. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.
Baran R; Kaoukhov A
J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):21-9. PubMed ID: 15649187
[TBL] [Abstract][Full Text] [Related]
20. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States.
Gupta AK; Joseph WS
J Am Podiatr Med Assoc; 2000; 90(10):495-501. PubMed ID: 11107710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]